Pharmacotherapeutic Group: Iron sucrose injection is used as Hematinic.
Pharmacology: Pharmacodynamics: Mechanism of Action: Following intravenous administration, iron sucrose is dissociated by the reticuloendothelial system into iron and sucrose. In hemodialysis patients on erythropoietin therapy treated with iron sucrose containing 100 mg of iron, three times weekly for three weeks, significant increases in serum ferritin and significant decreases in total iron binding capacity occurred four weeks from the initiation of iron sucrose treatment.
Pharmacokinetics: In healthy adults treated with intravenous doses of Iron sucrose Injection, its iron component exhibits first order kinetics with an elimination half-life of 6 hrs with total clearance of 1.2 L/h. Serum clearance of iron expected to be more rapid in iron deficient patients as compared to healthy individuals. Significant amount of the administered iron distributes in the liver, spleen and bone marrow and that the bone marrow is an iron trapping compartment and not a reversible volume of distribution. The sucrose component is eliminated mainly by urinary excretion. Approximately (5%) of the iron is eliminated in urine in 24 hrs at each dose.